Sun Pharmaceutical Industries has agreed to buy Organon for $14 a share in cash, valuing the U.S.-listed healthcare company at $11.75 billion including debt. The transaction folds a former Merck spinoff with $6.2 billion in 2025 revenue into Sun Pharma’s expanding global platform and marks one of the largest cross-border pharmaceutical acquisitions by an Indian company.
The deal is less about a single product line than about portfolio repair and market access. Organon brings more than 70 products, a meaningful women’s health franchise, biosimilars exposure and a commercial footprint across 140 countries. For Sun Pharma, which has built strength in specialty generics and selected innovative medicines, the acquisition adds scale in established brands and a ready-made route into biosimilars, a segment where pricing pressure is intense but global demand remains durable.
That matters because the pharma industry is splitting into two camps: companies with enough scale to absorb patent cliffs, regulatory complexity and launch costs, and everyone else. Sun Pharma is buying into the first group. The combined business would rank among the top 25 global drugmakers, with revenue of about $12.4 billion, operations in 150 countries and a more balanced mix between innovative medicines and legacy brands. It would also become a top-three player in global women’s health and the seventh-largest biosimilar company, according to the companies.
There is a financial catch. Organon carried $8.6 billion of debt at year-end 2025, and Sun Pharma expects post-deal net debt to EBITDA of 2.3 times. That is manageable, but it leaves less room for error if integration slips or if biosimilar margins compress faster than expected. Sun Pharma says EBITDA and cash flow will nearly double, which should help deleveraging over time. Investors will want to see whether those synergies come from real commercial overlap or from the usual promise of disciplined integration.
The acquisition also reflects a broader shift in global pharma capital allocation. Indian drugmakers have long competed on cost and manufacturing scale. Sun Pharma is now using that base to buy branded assets, deepen its presence in regulated markets and reduce dependence on commoditized generics. If regulators approve the transaction, expected to close in early 2027, the real test will be whether Sun Pharma can turn Organon’s global reach into pricing power rather than just a larger balance sheet.
Source: Company press release and Acquire.fyi's proprietary data
